Cumberland Pharmaceuticals (NASDAQ:CPIX) Upgraded at StockNews.com

Cumberland Pharmaceuticals (NASDAQ:CPIX) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

Cumberland Pharmaceuticals Stock Up 4.4 %

NASDAQ CPIX opened at $4.70 on Thursday. The business’s 50-day moving average is $4.72 and its 200 day moving average is $3.30. The stock has a market capitalization of $65.65 million, a PE ratio of -6.10 and a beta of -0.35. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. Cumberland Pharmaceuticals has a 1 year low of $1.04 and a 1 year high of $7.25.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 EPS for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP grew its holdings in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,649 shares of the specialty pharmaceutical company’s stock after buying an additional 18,271 shares during the period. Two Sigma Investments LP owned 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent SEC filing. 15.51% of the stock is currently owned by institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.